BIEL/Electrome: The Next UNICORN / $1B Startup (400% PPS

New Post Public Reply Private Reply Replies (0) Message Board
Bielionaire
218
BIEL/Electrome: The Next UNICORN / $1B Startup (400% PPS Surge So Far, Better Than 99.9% of All Stocks!)
The Medvi Playbook Is Repeating — But With a Bigger Market and Stronger Tailwinds

The conversation around BIEL is still stuck in the past — but the past is no longer relevant (except for the $40M+ tax-loss carryforward that makes the first $40M profit tax-free). The company that produced the 2024–2025 financials is not the company that exists today.

The pivot is complete.
The model has changed.
The market is only beginning to understand the scale of what’s unfolding.

This is the official beginning of the new story.

1. The 2024–2025 Financials Are Irrelevant — They Belong to the Old Book. Yes, 2025 revenue ticked up slightly and COGS dropped sharply, but:

These numbers reflect the pre-Electrome, pre-Haleon, pre-Veterinary era.

They are the last pages of the legacy standalone device seller model.

They have zero predictive value for the OEM future.

BIEL is no longer a consumer gadget company — it is now the exclusive hardware engine for an AI-native therapeutics ecosystem across:

human health

veterinary health

global consumer health

This is the Intel Inside transformation:

Electrome AI = the brain.
BIEL PEMF hardware = the engine.

The pivot just happened — so historical revenue is meaningless.

2. The OEM Future Is Measured in Millions — Not Thousands
BIEL now has three independent OEM engines, each with multi-million-dollar trajectories:

OEM Engine #1 — Human Health (Electrome)
PAINKILLER™ launch: $0.75M–$2.25M

AI expansion: $4M–$7M

National penetration: $7.5M–$22M annually

OEM Engine #2 — Veterinary AI
Elite performance animals: $500K–$1.2M

Specialty clinics: $3M–$7.5M

Global pet wearables: $12M–$25M+ annually

OEM Engine #3 — Haleon (Global Consumer Health)
Retail pilots: $2M–$5M

Global rollout: $15M–$35M

Mass-market wearables + subscriptions: $50M–$100M+ annually

These are phase-based rollouts already in motion, not distant hypotheticals.
Compared to this, the 2024–2025 financials are rounding errors.

3. Capital Factory Validation Makes the Past Irrelevant
Electrome is backed by Capital Factory, one of the most respected early-stage VC groups in the U.S.

Their involvement signals:

The tech is real

The platform is scalable

The hardware dependency on BIEL is locked in

Microcaps almost never get this halo — BIEL did.

Once institutional validation enters the picture, historical micro-revenues no longer matter — future cash flows do.

4. Float, Momentum, and AI Narrative = Re-Rating Catalysts
BIEL is gaining momentum — and it’s accelerating:

A historic 400% run - better than 99.9% of stocks (.0001 to .0005)

A vanishing float

A pending supply squeeze

This is the exact configuration that precedes violent re-ratings in microcaps.

And the AI narrative is the accelerant:

Electrome turns BIEL into a hot-sector AI hardware play.
This is why the market will price the future, not the past.

5. Profitability Is Within Reach — And the Model Is Ultra-Lean
BIEL has already demonstrated profitability:

Q3 2021 profit: $22,381 on $414,700 revenue

With COGS now dramatically lower and OEM volumes rising, the path to sustained profitability is short.

And the $40M tax-loss carryforward accelerates net profit conversion.

6. PPS Re-Rating Scenarios Make the Past Financials Meaningless
The market will re-rate based on OEM profit, not legacy device sales:

.001 — Technical breakout

.01 — Cash-flow positive (~$1.5M annual revenue)

.04 — $1M profit (P/E 1000)

.10 — $2.5M profit (P/E 1000)

$1.00 — After debt payoff + buyback

These valuations reflect the new business model, not the old one.

7. The Medvi Playbook — And Why It Maps Directly to BIEL/Electrome
Medvi went from a $20k idea to a $1.8B valuation by combining:

AI automation

healthcare workflows

data flywheels

scalable endpoints

BIEL/Electrome are now executing the same model, but with:

FDA-cleared hardware

a global distribution partner

VA deployments

celebrity investor validation

international adoption

a massive unmet need (chronic pain)

and a platform that scales like software

This is the strongest alignment of catalysts BIEL has seen in over a decade — and the closest real-world analog is Medvi’s $1.8B rise.

Electrome’s rise is BIEL’s inflection point.
The market hasn’t priced that in yet.

8. Publicity Is the Catalyst and Accelerant BIEL/Electrome Need
A rising PPS is not just a number — it is a media magnet.

BIEL: The Story Stock for 2026 @ PPS = .003
A move from .0001 to .003 is a 3,000% gain — larger than the 10-year percentage gains of Apple, Amazon, Netflix, Microsoft, Nvidia, Google, and others.

A move like that generates massive FREE PUBLICITY that would otherwise cost millions.

BIEL doesn’t need to spend a dollar on advertising.
A rising PPS creates the publicity for free.

The BIEL/Electrome narrative is tailor-made for media coverage:

FDA-cleared tech

AI-native therapeutics

celebrity investor

VA integration

global expansion

retail rollout

Make the PPS move — and the media will come to you.

Conclusion: The Old Book Is Closed — The New One Is a Multi-Vertical, AI-Native, VC-Validated Growth Engine
The 2024–2025 financials do not define BIEL — they are the last pages of the old story.

The new story is:

AI-native therapeutics

multi-industry OEM dominance

VC validation

global consumer-health integration

veterinary expansion

recurring hardware nodes

a closed-loop ecosystem

BIEL is no longer a $500K revenue company — it is a future multi-vertical OEM engine with $100M+ annual potential across its combined channels.

The past is irrelevant.
The future is asymmetric.

And the setup is even more asymmetric because BIEL is, functionally, a startup without startup risk:

five FDA clearances

validated manufacturing

VC-funded commercialization

zero early-stage burn

high-value patents pending (including vagus-nerve modulation)

and the first $40M profit is tax-free

This is the rare case where a microcap has the regulatory moat, the IP pipeline, and the VC-backed commercialization engine before the revenue inflection even begins.

The old book is closed.
The new one has just been released — and it’s a blockbuster.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

Alliance Entertainment Expands Leadership with Robert Oram

Updated Category News Views 137

Alliance Entertainment Welcomes Robert Oram as EVP Alliance Entertainment Holding Corporation (NASDAQ: AENT) has made a significant addition to its leadership team with the appointment of Robert Oram as the Executive Vice President. This strategic move, announced recently, aims to bolster the company's efforts in expanding its home entertainment division. Oram, a veteran...

Continue Reading
Teradyne Inc: Navigating AI Growth in Semiconductor Testing

Updated Category News Views 155

Teradyne Inc (NASDAQ: TER) was one of those stocks that had traders buzzing back in 2023 when it saw gains up to 50% early in the year. That kind of momentum, especially outpacing the Philadelphia Semiconductor Index, had folks dreaming big. But reality hit later on as the market pulled back, reminding everyone that nothing lasts forever in this volatile game. Market...

Continue Reading
Transforming Landscapers' Cash Flow with Duranta's Payments

Updated Category News Views 163

Duranta Unveils a Game-Changer for Landscapers' Payments Duranta, the AI-driven platform for landscaping professionals, is set to reshape how landscaping businesses handle payments. Recently, they introduced an innovative feature that embeds secure payment links directly into customer invoices. This new function streamlines transaction methods for landscapers, making it...

Continue Reading
Analyzing Market Trends: The Case of WR Berkley Stock

Updated Category News Views 146

Understanding WR Berkley and Its Market Position WR Berkley Corporation (NYSE: WRB) has been making headlines recently due to its fluctuating short interest levels. The company, known for its diverse insurance offerings, recorded a significant rise in its short percent of float, now standing at 22.48%. This figure comes from its recent announcement that approximately 7.96...

Continue Reading
Timbercreek Financial to Host Q4 Results Call - Key Details Inside

Updated Category News Views 153

Timbercreek Financial's Upcoming Conference Call Timbercreek Financial (TSX: TF) is gearing up for an important conference call to discuss its financial results for the last quarter. This call is set for 1:00 p.m. (ET) on a Wednesday. The insights into the company’s performance will be revealed shortly after the markets close. Stakeholders and interested parties are...

Continue Reading